AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30392584 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Watch notifications of pulse irregularity
Number of subjects: 419093
Study 29502043 — intervention group
Group type: EXPERIMENTAL
Intervention: Research interviews
Number of subjects: 40
Study 29502043 — intervention group
Group type: EXPERIMENTAL
Intervention: Research questionnaires
Number of subjects: 40
Study 29502043 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio recording of interviews
Number of subjects: 40
Study 29502043 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participation in the trial
Number of subjects: 40
Study 26497946 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐incision robotic cholecystectomy (SIRC)
Number of subjects: 60
Study 26497946 — intervention group
Group type: COMPARATOR
Intervention: Classic four‐port laparoscopic cholecystectomy (CLC)
Number of subjects: 60
Study 24444847 — intervention group
Group type: EXPERIMENTAL
Intervention: SHARP-at work intervention
Number of subjects: 158
Study 24444847 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 158
Study 21532737 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intravenous methylprednisolone (1 g) followed by oral prednisolone
Number of subjects: 42
Study 21532737 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone alone
Number of subjects: 42
Study 21532737 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (methylprednisolone + oral prednisolone and oral prednisolone alone)
Number of subjects: 42
Study 21532737 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 19630506 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA combined with general anesthesia (TEA group, n = 36)
Number of subjects: 72
Study 19630506 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA group, n = 36)
Number of subjects: 72
Study 19630506 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA combined with general anesthesia (TEA group)
Number of subjects: 72
Study 19630506 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA group)
Number of subjects: 72
Study 16253403 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-fibre-enriched formula (15 g/l)
Number of subjects: 15
Study 16253403 — intervention group
Group type: COMPARATOR
Intervention: Fibre-free formula
Number of subjects: 15
Study 15319700 — intervention group
Group type: EXPERIMENTAL
Intervention: Unkei-to
Number of subjects: 24
Study 15319700 — intervention group
Group type: COMPARATOR
Intervention: Toki-shakuyaku-san
Number of subjects: 24
Study 10902879 — intervention group
Group type: EXPERIMENTAL
Intervention: Palletization with different headroom conditions
Number of subjects: 21
Study 10902879 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery phase with different headroom conditions
Number of subjects: 21
Study 9495662 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril-based treatment
Number of subjects: 11019
Study 9495662 — intervention group
Group type: COMPARATOR
Intervention: Conventional antihypertensive therapy (diuretics and/or beta-blockers)
Number of subjects: 11019
Study 8095949 — intervention group
Group type: EXPERIMENTAL
Intervention: Full mask worn
Number of subjects: 30
Study 8095949 — intervention group
Group type: COMPARATOR
Intervention: No mask worn
Number of subjects: 30
Study 8095949 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask placement below the nose
Number of subjects: 30
Study 2939666 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (A (H3N2) + A (H1N1), 3.0‐3.4 micrograms of hemagglutinin per 0.2 ml)
Number of subjects: 6928
Study 2939666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6928
Study 4549504 — intervention group
Group type: EXPERIMENTAL
Intervention: Teasing of skin snips
Number of subjects: 0
Study 4549504 — intervention group
Group type: COMPARATOR
Intervention: Non-teasing methods of skin snips
Number of subjects: 0
Study 31133099 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (700 U) and 100 mg of calcium
Number of subjects: 101
Study 31133099 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 U of Vitamin D and 100 mg of calcium)
Number of subjects: 101
Study 27857024 — intervention group
Group type: EXPERIMENTAL
Intervention: LV5FU2
Number of subjects: 62
Study 27857024 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX
Number of subjects: 62
Study 25305637 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity program
Number of subjects: 386
Study 25305637 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical education classes
Number of subjects: 386
Study 22552359 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin 3-month depot (Direct Group)
Number of subjects: 0
Study 22552359 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin 1-month depot followed by 3-month depot (Switch Group)
Number of subjects: 0
Study 22552359 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Direct and Switch)
Number of subjects: 0
Study 21680862 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 30
Study 21680862 — intervention group
Group type: COMPARATOR
Intervention: No heat and moisture exchanger (HME)
Number of subjects: 30
Study 19947273 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina treatment on ten points using thumb and middle finger
Number of subjects: 240
Study 19947273 — intervention group
Group type: COMPARATOR
Intervention: Medication group (oral Chlorpheniramine and topical zinc oxide ointment or Youzhuoer ointment)
Number of subjects: 240
Study 19947273 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina treatment
Number of subjects: 240
Study 19947273 — intervention group
Group type: COMPARATOR
Intervention: Medication group
Number of subjects: 240
Study 16924568 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (NB) 4 mg/day
Number of subjects: 30
Study 16924568 — intervention group
Group type: COMPARATOR
Intervention: Systemic corticosteroid (SC) 1 mg/kg/day methylprednisolone
Number of subjects: 30
Study 16924568 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (NB) plus systemic corticosteroid (SC)
Number of subjects: 30
Study 15575855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovide (0.5% malathion) for 20 minutes
Number of subjects: 41
Study 15575855 — intervention group
Group type: COMPARATOR
Intervention: Nix (1% permethrin)
Number of subjects: 41
Study 11606016 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST
Number of subjects: 20
Study 11606016 — intervention group
Group type: EXPERIMENTAL
Intervention: SLOW
Number of subjects: 20
Study 11606016 — intervention group
Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 20
Study 9075036 — intervention group
Group type: EXPERIMENTAL
Intervention: High thoracic epidural anesthesia (HTE) with 2% lidocaine 5 ml
Number of subjects: 24
Study 9075036 — intervention group
Group type: COMPARATOR
Intervention: Low thoracic epidural anesthesia (LTE)
Number of subjects: 24
Study 8503338 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 125 mg
Number of subjects: 26
Study 8503338 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg
Number of subjects: 26
Study 8503338 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 375 mg
Number of subjects: 26
Study 8503338 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 750 mg
Number of subjects: 26
Study 8503338 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 1125 mg
Number of subjects: 26
Study 8503338 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 1500 mg
Number of subjects: 26
Study 8503338 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 375 mg/day
Number of subjects: 26
Study 8503338 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 1500 mg/day
Number of subjects: 26
Study 8503338 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (various doses)
Number of subjects: 26
Study 3100110 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 IU hGH, subcutaneously, 12-hourly for 72 hours before GHRH test
Number of subjects: 14
Study 3100110 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 IU hGH, single subcutaneous dose, 12 hours before GHRH test
Number of subjects: 14
Study 3100110 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 IU hGH, intravenously, followed by i.v. GHRH 3 hours later
Number of subjects: 14
Study 3100110 — intervention group
Group type: COMPARATOR
Intervention: Placebo, subcutaneously, 12-hourly for 72 hours before GHRH test
Number of subjects: 14
Study 3100110 — intervention group
Group type: COMPARATOR
Intervention: Placebo, intravenously, followed by i.v. GHRH 3 hours later
Number of subjects: 14
Study 27637735 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Functional (Cog-Fun) intervention
Number of subjects: 107
Study 27637735 — intervention group
Group type: COMPARATOR
Intervention: Control group (received treatment after crossover)
Number of subjects: 107
Study 29408304 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated prompts
Number of subjects: 27000
Study 29408304 — intervention group
Group type: EXPERIMENTAL
Intervention: Live prompts
Number of subjects: 27000
Study 29408304 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of automated plus live prompts
Number of subjects: 27000
Study 29408304 — intervention group
Group type: COMPARATOR
Intervention: Direct-mail fecal immunochemical testing (FIT) program
Number of subjects: 27000
Study 27226262 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-blocking glasses (BB)
Number of subjects: 32
Study 27226262 — intervention group
Group type: COMPARATOR
Intervention: Placebo (clear glasses)
Number of subjects: 32
Study 24738550 — intervention group
Group type: EXPERIMENTAL
Intervention: Team context (three-person teams)
Number of subjects: 78
Study 24738550 — intervention group
Group type: COMPARATOR
Intervention: Individual context
Number of subjects: 78
Study 24738550 — intervention group
Group type: EXPERIMENTAL
Intervention: Both contexts (team and individual)
Number of subjects: 78
Study 24738550 — intervention group
Group type: EXPERIMENTAL
Intervention: Team context (for students with pre-test scores ≤25.8%)
Number of subjects: 78
Study 23748185 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency exercise group (HF-EG)
Number of subjects: 162
Study 23748185 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency exercise group (LF-EG)
Number of subjects: 162
Study 20601162 — intervention group
Group type: EXPERIMENTAL
Intervention: Afrocentric identity group
Number of subjects: 560
Study 20601162 — intervention group
Group type: COMPARATOR
Intervention: Non-Afrocentric identity group
Number of subjects: 560
Study 20601162 — intervention group
Group type: EXPERIMENTAL
Intervention: Afrocentric participants
Number of subjects: 560
Study 17595176 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based individualized precontemplation feedback (PCF)
Number of subjects: 0
Study 17595176 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based individualized contemplation feedback (CF)
Number of subjects: 0
Study 17595176 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based individualized action feedback (AF)
Number of subjects: 0
Study 17595176 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16483391 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose, high-concentration localized botulinum toxin A (BTX-A) injections (total dose 82-220 units, mean 139 [SD 37.48]; dilution 100 units/0.5ml)
Number of subjects: 42
Study 16483391 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose, high-concentration localized botulinum toxin A (BTX-A) injections
Number of subjects: 42
Study 15363241 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming group (n = 20)
Number of subjects: 40
Study 15363241 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 40
Study 11194696 — intervention group
Group type: EXPERIMENTAL
Intervention: Sponsor kit of promotional materials
Number of subjects: 0
Study 11194696 — intervention group
Group type: COMPARATOR
Intervention: Healthway staff attendance
Number of subjects: 0
Study 9139168 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval exercise training on cycle ergometer (IntCT) with 30‐s work phases/60‐s recovery phases and on treadmill with 60‐s work and recovery phases each for 3 weeks.
Number of subjects: 18
Study 8440356 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO‐identical platelets
Number of subjects: 40
Study 8440356 — intervention group
Group type: COMPARATOR
Intervention: ABO‐unmatched platelets
Number of subjects: 40
Study 4027872 — intervention group
Group type: EXPERIMENTAL
Intervention: PALA alone (800 to 1000 mg/m2 per day for 5 days every 2 weeks)
Number of subjects: 63
Study 4027872 — intervention group
Group type: EXPERIMENTAL
Intervention: PALA + 5-FU (PALA: 400 mg/m2 per day for 5 days, 5-FU: 300 mg/m2 per day for 5 days every 28 days)
Number of subjects: 63
Study 4027872 — intervention group
Group type: COMPARATOR
Intervention: 5-FU alone (300 to 400 mg/m2 per day for 5 days every 21 days)
Number of subjects: 63
Study 30513988 — intervention group
Group type: EXPERIMENTAL
Intervention: Juçara supplementation (5 g juçara freeze-dried pulp)
Number of subjects: 27
Study 30513988 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 g of maltodextrin)
Number of subjects: 27
Study 27263403 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Hb concentration ≤109 g/L during 24-28 weeks of gestation
Number of subjects: 17193
Study 27263403 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Hb concentration 120-129 g/L during 24-28 weeks of gestation
Number of subjects: 17193
Study 27263403 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Hb concentration ≥130 g/L during 24-28 weeks of gestation
Number of subjects: 17193
Study 24631162 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Number of subjects: 2332
Study 24631162 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 2332
Study 22723003 — intervention group
Group type: EXPERIMENTAL
Intervention: AA genotype
Number of subjects: 320
Study 22723003 — intervention group
Group type: EXPERIMENTAL
Intervention: AC+CC genotype
Number of subjects: 320
Study 22723003 — intervention group
Group type: EXPERIMENTAL
Intervention: A allele frequency
Number of subjects: 320
Study 20466223 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1.5 mg/kg
Number of subjects: 68
Study 20466223 — intervention group
Group type: COMPARATOR
Intervention: Meperidine 1 mg/kg
Number of subjects: 68
Study 18652922 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraction Stress Test
Number of subjects: 0
Study 18652922 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonstress Test
Number of subjects: 0
Study 18652922 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibroacoustic Stimulation
Number of subjects: 0
Study 18652922 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic Fluid Volume Assessment
Number of subjects: 0
Study 18652922 — intervention group
Group type: EXPERIMENTAL
Intervention: Biophysical Profile
Number of subjects: 0
Study 18652922 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Biophysical Profile
Number of subjects: 0
Study 16188816 — intervention group
Group type: COMPARATOR
Intervention: Implementation package alone (group A)
Number of subjects: 34
Study 16188816 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation package and visits from a facilitator (group B)
Number of subjects: 34
Study 12811420 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-TOC scintigraphy
Number of subjects: 32
Study 10232312 — intervention group
Group type: EXPERIMENTAL
Intervention: co‐trimoxazole (800 mg/160 mg)
Number of subjects: 771
Study 10232312 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 771
Study 8923159 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat products
Number of subjects: 217
Study 8923159 — intervention group
Group type: COMPARATOR
Intervention: Full-fat products
Number of subjects: 217
Study 1987739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary brachytherapy boost (10-15 Gy) following external beam radiation therapy (60-64 Gy).
Number of subjects: 146
Study 1987739 — intervention group
Group type: COMPARATOR
Intervention: External beam radiation therapy alone (65-70 Gy).
Number of subjects: 146
Study 6132178 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol, 300-500 mg intravenously
Number of subjects: 24
Study 6132178 — intervention group
Group type: COMPARATOR
Intervention: Naloxone, 30-40 mg intravenously
Number of subjects: 24
Study 6132178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6132178 — intervention group
Group type: COMPARATOR
Intervention: High-dose corticosteroids
Number of subjects: 24
Study 31706337 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant stereotactic radiosurgery (SRS)
Number of subjects: 72
Study 29353631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 5% aqueous solution (double dose)
Number of subjects: 50
Study 29353631 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine 0.12%
Number of subjects: 50
Study 29353631 — intervention group
Group type: COMPARATOR
Intervention: Plantago major extract
Number of subjects: 50
Study 29353631 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 50
Study 25420791 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE EES (everolimus-eluting stents)
Number of subjects: 64
Study 25420791 — intervention group
Group type: COMPARATOR
Intervention: BioMatrix BES (biolimus A9-eluting stents)
Number of subjects: 64
Study 25443604 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified radial approach
Number of subjects: 80
Study 25443604 — intervention group
Group type: COMPARATOR
Intervention: Modified Cox's Maze III
Number of subjects: 80
Study 22938716 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 400 μg daily
Number of subjects: 943
Study 22938716 — intervention group
Group type: COMPARATOR
Intervention: Nedocromil 16 mg daily
Number of subjects: 943
Study 22938716 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoids (higher doses in first 2 years)
Number of subjects: 943
Study 20539303 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) providing 800‐1,000 kcal/day during 8 weeks
Number of subjects: 701
Study 18265850 — intervention group
Group type: EXPERIMENTAL
Intervention: Pound of lead
Number of subjects: 0
Study 18265850 — intervention group
Group type: COMPARATOR
Intervention: Pound of feathers
Number of subjects: 0
Study 15730557 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus Sulfadoxine/Pyrimethamine (AS+SP)
Number of subjects: 269
Study 15730557 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus Amodiaquine (AS+AQ)
Number of subjects: 269
Study 12784695 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM) practices in stroke management
Number of subjects: 0
Study 12784695 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCT)
Number of subjects: 0
Study 12784695 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Unit (SU)
Number of subjects: 0
Study 12784695 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines for acute stroke management
Number of subjects: 0
Study 12784695 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Scales
Number of subjects: 0
Study 9849415 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive users
Number of subjects: 422
Study 9849415 — intervention group
Group type: COMPARATOR
Intervention: Non-oral contraceptive users
Number of subjects: 422
Study 8520707 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E, Vitamin C, Beta-carotene
Number of subjects: 8000
Study 8520707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8000
Study 2152803 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg oral solution
Number of subjects: 8
Study 2152803 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg tablet
Number of subjects: 8
Study 2152803 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tablet
Number of subjects: 8
Study 2152803 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg intravenous infusion
Number of subjects: 8
Study 2152803 — intervention group
Group type: EXPERIMENTAL
Intervention: All oral doses
Number of subjects: 8
Study 380912 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (2.0 to 2.5 mg per kg body weight, single dose on 1 day per week for 4 months)
Number of subjects: 33
Study 380912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 31658134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil therapy (nicorandil 10 mg three times daily plus hydration)
Number of subjects: 300
Study 31658134 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (hydration only)
Number of subjects: 300
Study 31658134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil therapy
Number of subjects: 300
Study 31056733 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol (200 mg/day)
Number of subjects: 415
Study 31056733 — intervention group
Group type: COMPARATOR
Intervention: aspirin (100 mg/day)
Number of subjects: 415
Study 28062625 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (hs-TnI) >26 ng/L
Number of subjects: 15833
Study 28062625 — intervention group
Group type: COMPARATOR
Intervention: High-sensitivity troponin I (hs-TnI) <1.9 ng/L
Number of subjects: 15833
Study 28062625 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar in patients with hs-TnI >26 ng/L
Number of subjects: 15833
Study 28062625 — intervention group
Group type: COMPARATOR
Intervention: Vorapaxar in patients with hs-TnI <1.9 ng/L
Number of subjects: 15833
Study 26440235 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at a rate of 120 mcg/kg/min starting immediately after CPB and maintained throughout surgery and for 6 hours in ICU
Number of subjects: 24
Study 26440235 — intervention group
Group type: COMPARATOR
Intervention: Propofol at a dose of 30-50 mcg/kg/min starting at chest closure and continued for 6 hours in ICU
Number of subjects: 24
Study 24337339 — intervention group
Group type: EXPERIMENTAL
Intervention: Antistigma photovoice intervention
Number of subjects: 82
Study 24337339 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 82